CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于 TREM1/DAP12 的新型多链 CAR-T 细胞靶向 PTK7 用于卵巢癌治疗
英文原题：A novel TREM1/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy.
查看英文原题
A novel TREM1/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管CAR-T 细胞疗法在血液肿瘤中显示出成功，但其对实体瘤（包括卵巢癌）的有效性仍不令人满意。本研究旨在开发并评估通过TREM1/DAP12信号传导靶向PTK7的新型CAR-T（CAR-T）细胞对卵巢癌的疗效。采用免疫组化染色和流式细胞术分析评估PTK7在卵巢癌组织和细胞中的表达。通过实时细胞分析和酶联免疫吸附试验在体外评估PTK7 CAR-T 细胞的抗肿瘤作用，并通过异种移植肿瘤模型在体内评估。PTK7在卵巢癌组织和细胞中显著表达。基于TREM1/DAP12信号传导的靶向PTK7的CAR-T 细胞在体外对表达PTK7的卵巢癌细胞表现出强效细胞毒性，并在体内有效根除肿瘤。我们的研究结果表明，基于TREM1/DAP12的PTK7 CAR-T 细胞有潜力作为卵巢癌的治疗策略。需要进一步研究以评估该方法在临床试验中的安全性和有效性。
展开英文摘要原文
While CAR-T cell therapy has shown success against hematological tumors, its effectiveness for solid tumors, including ovarian cancer, remains unsatisfactory.
This study aimed to develop and evaluate the efficacy of novel chimeric antigen receptor T (CAR-T) cells targeting PTK7 through TREM1/DAP12 signaling against ovarian cancer. The expression of PTK7 in ovarian cancer tissues and cells was evaluated using immunohistochemical staining and flow cytometric analysis.
The anti-tumor effects of PTK7 CAR-T cells were assessed in vitro using real-time cell analysis and enzyme-linked immunosorbent assay, and in vivo using a xenograft tumor model. PTK7 was significantly expressed in ovarian cancer tissues and cells. PTK7-targeting CAR-T cells based on TREM1/DAP12 signaling exhibited potent cytotoxicity against ovarian cancer cells expressing PTK7 in vitro, and effectively eradicated tumors in vivo.
Our findings suggest that TREM1/DAP12-based PTK7 CAR-T cells have potential as a treatment strategy for ovarian cancer.
Further studies are needed to evaluate the safety and efficacy of this approach in clinical trials.
论文信息
- 作者
- Xu T、Wang C、Wang X、Wang E、Wang B、Sun M
- 第一作者单位
- Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.China
- 通讯作者单位
- Suzhou Cancer Center Core Laboratory, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou Municipal Hospital, Gusu School, Baita West Road #16, Suzhou, 215001, People's Republic of China. sunming348@hotmail.com.China
- 期刊
- Medical oncology (Northwood, London, England)2023 Jul 5
- 原文标识
- PubMed 37405498 · DOI 10.1007/s12032-023-02084-9